2022 Annual Meeting | C2 - Lewy Body Dementia

Date Saturday 04/02/22

Time 07:00 AM - 09:00 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Melissa Armstrong, MD, MSc, FAAN, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should be able to recognize prodromal presentations of Lewy body dementia; be able to review assessments and biomarkers used in the clinical diagnosis of Lewy body dementia, including recent FDA approvals; and be able to identify pharmacologic and non-pharmacologic approaches to treating individuals with Lewy body dementia.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:35 AM PDT	Speaker	Recognizing Prodromal Lewy Body Dementia and Making the Diagnosis Samantha K. Holden, MD, MS, FAAN
07:00 AM - 09:00 AM PDT	Speaker	walk in slides Melissa Armstrong, MD, MSc, FAAN, FAAN
07:35 AM - 08:10 AM PDT	Speaker	Diagnostic Tests and Biomarkers for Lewy Body Dementia Ryan A. Townley, MD
08:10 AM - 08:45 AM PDT	Speaker	Pharmacologic and Non-pharmacologic Strategies for Treating Lewy Body Dementia Melissa Armstrong, MD, MSc, FAAN, FAAN
08:45 AM - 09:00 AM PDT	Q&A	Questions and Answers Melissa Armstrong, MD, MSc, FAAN, FAAN, Samantha K. Holden, MD, MS, FAAN, Ryan A. Townley, MD

Faculty Disclosures
Melissa Armstrong, MD, MSc, FAAN, FAAN	The institution of Dr. Armstrong has received research support from National Institutes of Health. The institution of Dr. Armstrong has received research support from Florida Department of Health. The institution of Dr. Armstrong has received research support from Lewy Body Dementia Association. Dr. Armstrong has received personal compensation in the range of $5,000-$9,999 for serving as a DSMB member with Alzheimer's Clinical Trials Consortium. Dr. Armstrong has received personal compensation in the range of $5,000-$9,999 for serving as a DSMB member with Alzheimer's Disease Cooperative Study. Dr. Armstrong has received personal compensation in the range of $500-$4,999 for serving as a DSMB member with National Institutes of Health. Dr. Armstrong has a non-compensated relationship as a Member, Scientific Advisory Council with Lewy Body Dementia Association that is relevant to AAN interests or activities.
Samantha K. Holden, MD, MS, FAAN	The institution of Dr. Holden has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics.
Ryan A. Townley, MD	Dr. Townley has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for AAN.

��ɫ��

��ɫ��